• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Details
Files
DOI
10.7892/boris.78709
Publisher DOI
10.1038/leu.2015.281
PubMed ID
26464170
Abstract
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P<0.001) and non-high-risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P=0.005) and free of drug treatment (56% vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.Leukemia advance online publication, 20 November 2015; doi:10.1038/leu.2015.281.
Date Issued
2016
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Author(s)
Gratwohl, A
Pfirrmann, M
Zander, A
Kröger, N
Beelen, D
Novotny, J
Nerl, C
Scheid, C
Spiekermann, K
Mayer, J
Sayer, H G
Falge, C
Bunjes, D
Döhner, H
Ganser, A
Schmidt-Wolf, I
Schwerdtfeger, R
Baurmann, H
Kuse, R
Schmitz, N
Wehmeier, A
Th Fischer, J
Ho, A D
Wilhelm, M
Goebeler, M-E
Lindemann, H W
Bormann, M
Hertenstein, B
Schlimok, G
Baerlocher, Gabriela M.
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Departement Klinische Forschung, Forschungsgruppe Hämatologie (Erwachsene)  
Aul, C
Pfreundschuh, M
Fabian, M
Staib, P
Edinger, M
Schatz, M
Fauser, A
Arnold, R
Kindler, T
Wulf, G
Rosselet, A
Hellmann, A
Schäfer, E
Prümmer, O
Schenk, M
Hasford, J
Heimpel, H
Hossfeld, D K
Kolb, H-J
Büsche, G
Haferlach, C
Schnittger, S
Müller, M C
Reiter, A
Berger, U
Saußele, S
Hochhaus, A
Hehlmann, R
Additional Credits
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor  
Journal
Leukemia
Publisher
Nature Publishing Group
ISSN
0887-6924
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify